This is a competing renewal application for the Pacific Northwest (PNW) Node, which joined the NIDA National Drug Abuse Treatment Clinical Trials Network (CTN) in January, 2001. Our primary aim is to continue our active support of the CTN's mission, to """"""""improve the quality of drug abuse treatmentthroughout the country using science as the vehicle"""""""" by conducting studies of behavioral, pharmacological, and ntegrated behavioral-pharmacological treatment interventions in rigorous, multi-site clinical trials to determine their effectiveness across a broad range of CTP settings and diversified patient populations and ensuring the transfer of research results to treatment providers. In order to effectively meet these objectives, the (PNW) Node proposes to: Maintain an effective, bidirectional partnership and working relationship among researchers, treatment providers, and policy makers Maintain and expand a highly successful and well-established treatment research infrastructure within the Node Expand the Node's geographical reach by incorporating a community-based treatment program (CTP) from Alaska, also broadening the ethnic diversity within the Node Enhance the Node's capacity to conduct pharmacotherapy trials and respond more rapidly to emerging public health priorities by adding a larger, highly research-experiencedCTP ? Broaden and deepen the clinical research expertise of the Node by adding a number of affiliated investigators who bring a wealth of experience from prior intervention trials on topic areas directly relevant to the CTN We have successfully contributed to the CTN's mission over the past 6 years and anticipate continuing to do so in the future. From a public health perspective, our continued success in conducting such research and dissemination as part of the CTN will facilitate empirically supported, evidence-based interventions being implemented in community-based treatment programs, with a resultant improvement in the quality and effectiveness of substance abuse treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013714-06S1
Application #
7497396
Study Section
Special Emphasis Panel (ZDA1-MXG-S (07))
Program Officer
Dobbins, Ronald
Project Start
2001-01-10
Project End
2010-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
6
Fiscal Year
2007
Total Cost
$143,867
Indirect Cost
Name
University of Washington
Department
Psychology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Miguel, André Q C; Madruga, Clarice S; Simões, Viviane et al. (2018) Crack cocaine users views regarding treatment with contingency management in Brazil. Subst Abuse Treat Prev Policy 13:7
Newville, Howard; Sorensen, James L; Hatch-Maillette, Mary et al. (2018) Temporal Relationship of Sex Risk Behaviors and Substance Use Severity Among Men in Substance Use Treatment. J Sex Res 55:1056-1064
Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Barbosa-Leiker, Celestina; McPherson, Sterling; Layton, Matthew E et al. (2018) Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. Am J Drug Alcohol Abuse 44:488-496
Miguel, André Q C; Madruga, Clarice S; Cogo-Moreira, Hugo et al. (2018) Sociodemographic Characteristics, Patterns of Crack Use, Concomitant Substance Use Disorders, and Psychiatric Symptomatology in Treatment-Seeking Crack-Dependent Individuals in Brazil. J Psychoactive Drugs 50:367-372
Lee, Joshua D; Nunes Jr, Edward V; Novo, Patricia et al. (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391:309-318
McPherson, Sterling; Orr, Michael; Lederhos, Crystal et al. (2018) Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence. Behav Pharmacol 29:370-374
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Wendt, Dennis C; Hallgren, Kevin A; Daley, Dennis C et al. (2017) Predictors and Outcomes of Twelve-Step Sponsorship of Stimulant Users: Secondary Analyses of a Multisite Randomized Clinical Trial. J Stud Alcohol Drugs 78:287-295

Showing the most recent 10 out of 126 publications